Taiho Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Clinical Trials
97
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (94 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Conditions
- NSCLC, Stage IBNSCLC, Stage IIIA
- Interventions
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT07128199
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
- Conditions
- Advanced/Metastatic Cancer
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06506955
- Locations
- 🇫🇷
Institut De Cancerologie Strasbourg, Strasbourg, France
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
🇫🇷Institut Paoli-Calmettes, Marseille, France
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT05973773
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States
🇺🇸Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson, Henderson, Nevada, United States
🇺🇸Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie, Henderson, Nevada, United States
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT05967689
- Locations
- 🇰🇷
National Cancer Center - Korea, Goyang-si, Gyeonggi-do, Korea, Republic of
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Conditions
- Esophageal Squamous Cell CancerLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerSiewert Type 1 GEJ CancerPancreatic CancerEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05945823
- Locations
- 🇺🇸
University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next